Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

This study has been completed.
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00582556
First received: December 19, 2007
Last updated: June 2, 2014
Last verified: June 2014
  Purpose

The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma. In addition, the researchers will also determine the effects of treatment with Zometa® on peripheral blood markers of bone turnover, on peripheral blood gd T-cell frequencies and function, and to determine if the above treatments elicit prostate antigen-specific IgG immune responses. The effects of the above treatments on serial serum PSA measurements will also be examined.


Condition Intervention Phase
Prostate Cancer
Drug: Zometa
Drug: zometa
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Zometa on Bone Mineral Density on Patients With Stage D Prostate Cancer Undergoing Androgen Ablation Therapy

Resource links provided by NLM:


Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • The Number of Subjects Who Had Either an Increase or Decrease on Bone Mineral Density of the Lumbar Spine and Femoral Neck in Men Undergoing Androgen Deprivation Therapy for Prostate Adenocarcinoma. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Effects on bone mineral density were measured at four locations at six month intervals for 24 months.


Secondary Outcome Measures:
  • The Number of Subjects Who Had a Significant Increase of Peripheral Blood Markers of Bone Turnover. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Serum bone-specific alkaline phosphatase was collected as the blood marker of bone turnover.

  • Number of Subjects Had a Significant Change in Immune Markers. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Immune markers were measured by isolating gamma-delta T cells one month after treatment with zoledronic acid.

  • Number of Subjects With Decreases in Prostate Specific Antigen (PSA) After Zoledronic Acid Prior to Beginning Androgen Deprivation Therapy [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

    PSA response was measured by observing the serum PSA one week after beginning zoledronic acid and prior to beginning androgen deprivation therapy.

    Arm 2 and Arm 3 were not able to be assessed for this endpoint as all subjects were on androgen deprivation prior to receiving zoledronic acid.



Enrollment: 44
Study Start Date: April 2003
Study Completion Date: March 2013
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
Drug: Zometa
GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
Other Names:
  • zoledronic acid
  • lupron
  • zolodex
Active Comparator: 2
GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given at mo 6
Drug: zometa
GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
Other Names:
  • zoledronic acid
  • lupron
  • zolodex
Active Comparator: 3
GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
Drug: Zometa
GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
Other Names:
  • zolodronic acid
  • lupron
  • zolodex

Detailed Description:

Castration by GnRH agonist therapy with or without androgen antagonists has been a mainstay for advanced prostate cancer. One of the most significant side effects of the use of androgen ablative therapies has been a decrease in bone mineral density, potentially placing patients at greater risk of osteoporosis and bone fractures. It is prudent to anticipate this adverse effect of therapy and to minimize its severity with appropriate and timely pharmacologic intervention. Zometa is a bisphosphonates and bisphosphonates are effective inhibitors of osteoclastic bone resorption. Recent studies have shown that other bisphosphonates were able to reduce the bone loss observed after 24 and 48 weeks of treatment with a GnRH analogue. An unanswered question remains, however, in how frequently these agents should be employed in clinical practice.

This is a three-arm randomized trial of Zometa® on bone mineral density in subjects with stage D prostate cancer undergoing androgen ablation therapy. If subjects are enrolled in Arm 1, the GnRH analogue would be administered every 3 months for 1 year. Four milligrams of Zometa® would be administered IV over 15 minutes 7 days prior to beginning androgen deprivation therapy. If subjects are enrolled in Arm 2, the GnRH analogue would be administered every 3 months for one year, and 4 mg of Zometa® would be administered IV over 15 minutes at month 6. If subjects are enrolled in Arm 3, the GnRH analogue is administered every 3 months for 1 year, with 4 mg of Zometa® administered IV over 15 minutes monthly for 6 months, beginning at month 6.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a histologic diagnosis of adenocarcinoma of the prostate.
  • For patients without clinical metastasis treated by surgery, serum PSA values must be > 0.2 ng/ml by two measurements at least two weeks apart. In patients treated with ablative radiation therapy without clinical metastasis, three consecutive increases in serum PSA must be documented, with at least a one-month interval between values with the final PSA > 2ng/m as evidence of biochemical PSA failure. P
  • Patients who have not had prior primary therapy such as radiation or surgery, are required to have a detectable PSA of at least 0.2 ng/ml.
  • Patients with evidence of metastatic disease are eligible irrespective of serum PSA level.
  • Prior history of a second malignancy is allowed if treated with curative intent and patient has been free of disease greater than five years
  • ECOG performance status of < 2.

Exclusion Criteria:

  • Prior treatment with a GnRH analogue or anti-androgen.
  • Evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids, or radiation therapy to bones, within 6 months of study enrollment
  • Current or treatment within 4 weeks with estrogen or estrogenic agents (including herbal compound PC-SPES)
  • Current or treatment within 4 weeks with herbal compounds for prostate cancer such as PC-SPES or saw palmetto
  • Current or treatment within 4 weeks with megestrol
  • Current or prior treatment with a bisphosphonate, calcitonin, or other bone resorptive/anabolic agents
  • Current use of oral corticosteroids or any such use within the past 6 months
  • Current use of potentially bone-toxic anticonvulsants (phenytoin, or carbamazepine)
  • History of orchiectomy
  • Hypocalcemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00582556

Locations
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Novartis Pharmaceuticals
Investigators
Principal Investigator: Douglas McNeel, MD University of Wisconsin, Madison
  More Information

No publications provided

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00582556     History of Changes
Other Study ID Numbers: CO02807, CO02807
Study First Received: December 19, 2007
Results First Received: February 24, 2014
Last Updated: June 2, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Wisconsin, Madison:
bone mineral density

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Androgens
Zoledronic acid
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on July 24, 2014